Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × NIH × golimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Diabetes Mellitus, Type 1 1

Interventions

Specimen Handling 11 Magnetic Resonance Spectroscopy 10 Cyclophosphamide 9 Nivolumab 6 Drug Therapy 6 Dexamethasone 6 Biopsy 6 Biological Therapy 6 fludarabine 5 aldesleukin 5 Ipilimumab 5 Doxorubicin 5 antineoplaston AS 2-1 4 antineoplaston A10 4 Rituximab 4 Etoposide 4 Complementary Therapies 4 Cisplatin 4 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4 olaparib 3 copanlisib 3 atezolizumab 3 X-Rays 3 Vincristine 3 Surgical Procedures, Operative 3 Phantoms, Imaging 3 Fluorouracil 3 Filgrastim 3 Chemotherapy, Adjuvant 3 CTLA-4 Antigen 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04729296 2021-12-02

Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2 Withdrawn

Diabetes Mellitus, Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡